Brian Posner Acquires 2,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Posted by George Bondi on Jun 11th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Brian Posner purchased 2,000 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were purchased at an average cost of $16.94 per share, for a total transaction of $33,880.00. Following the completion of the purchase, the director directly owned 24,500 shares in the company, valued at $415,030. The trade was a 8.89% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $17.67 on Thursday. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The stock has a market capitalization of $2.92 billion, a P/E ratio of -5.49 and a beta of 1.09. The firm’s 50-day moving average is $18.27 and its two-hundred day moving average is $18.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the firm earned ($1.05) EPS. Equities analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 15th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Sanford C. Bernstein raised their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, HC Wainwright decreased their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Get Our Latest Research Report on Dyne Therapeutics

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DYN. T. Rowe Price Investment Management Inc. lifted its position in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after buying an additional 14,727,667 shares in the last quarter. Orbis Allan Gray Ltd acquired a new position in Dyne Therapeutics during the fourth quarter valued at approximately $93,926,000. Adage Capital Partners GP L.L.C. acquired a new position in Dyne Therapeutics during the second quarter valued at approximately $30,378,000. Perceptive Advisors LLC lifted its position in Dyne Therapeutics by 543.7% during the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock valued at $68,048,000 after buying an additional 2,938,500 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock valued at $38,119,000 after buying an additional 2,565,570 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.